Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164859
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Madera, Jessica | - |
dc.contributor.author | Such, Pedro | - |
dc.contributor.author | Zhang, Peter | - |
dc.contributor.author | Baker, Ross A. | - |
dc.contributor.author | Grande i Fullana, Iria | - |
dc.date.accessioned | 2020-06-09T07:22:34Z | - |
dc.date.available | 2020-06-09T07:22:34Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1176-6328 | - |
dc.identifier.uri | http://hdl.handle.net/2445/164859 | - |
dc.description.abstract | Purpose: There is growing agreement that definitions of "recovery" in bipolar-I disorder (BP-I) should include functional outcomes beyond sustained symptomatic remission. In this post-hoc analysis, we assessed functional recovery rates according to the validated Functioning Assessment Short Test (FAST) in participants with BP-I after 52 weeks of maintenance treatment with aripiprazole once monthly (AOM). Patients and methods: Rates offunctional recovery with AOM 400 were investigated in two 52-week studies. NCT01567527 was a placebo-controlled, double-blind, randomized-withdrawal study and NCT01710709 was an open-label study. Functional recovery, assessed at the end of the respectivemaintenancephases,wasdefinedasatotal FASTscoreof ≤11for8consecutive weeks. Results: Post-hoc analyses included 229 patients from the randomized-withdrawal study (AOM 400 n=116; placebo n=113). The open-label study included 402 patients (including 321 de novo patients and 81 rollover patients who had completed the randomized-withdrawal study). In the randomized-withdrawal study, functional recovery was achieved by 30.2% (n=35) of the AOM 400 group compared with 24.8% (n=28) in the placebo group. The difference was not statistically significant (p=0.39). In the open-label study, 36% (n=116) of de novo patients and 43% (n=35) of rollover patients had functionally recovered after 52 weeks of AOM 400 treatment. Conclusion: These data highlight the utility of a sustained FAST total score of ≤11 as a definition of recovery and emphasize the possibility of achieving this ambitious treatment goal with effective long-term treatment. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/NDT.S209700 | - |
dc.relation.ispartof | Neuropsychiatric Disease and Treatment, 2019, num. 15, p. 2325-2338 | - |
dc.relation.uri | https://doi.org/10.2147/NDT.S209700 | - |
dc.rights | cc-by-nc (c) Madera, Jessica et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Trastorn bipolar | - |
dc.subject.classification | Psiquiatria | - |
dc.subject.other | Manic-depressive illness | - |
dc.subject.other | Psychiatry | - |
dc.title | Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 698764 | - |
dc.date.updated | 2020-06-09T07:22:34Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31616148 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) Articles publicats en revistes (Institut de Neurociències (UBNeuro)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
698764.pdf | 510.98 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License